Genscript Biotech Corp (1548) Fair Value & Analysis
Healthcare · HK · Market cap HK$26.7B (≈ $3.4B) · ISIN KYG3825B1059
What is Genscript Biotech Corp really worth?
A solid business, but trading 103% above our fair value of HK$15.52.
Strengths
Risks
Fair value as of: Aug 20, 2026
From 13 valuation models · updated 16 days ago
Fair value updated Aug 20, 2026, revised from HK$15.14 to HK$15.52 (+2.5%) since Aug 13, 2026. Share price +67.8% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (HK$19.42). The favourable scenario is already priced in.
- Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 20, 2026.
How to read this chart
60‑month range HK$8.23 – HK$41.95 · fair‑value band HK$11.63 – HK$19.42 · the HK$31.46 price screens above the HK$15.52 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 20, 2026.
Analysis
Genscript Biotech Corp (1548) currently trades at HK$31.46, while our model-based Fair Value estimate is HK$15.52, implying the stock looks roughly 102.7% overvalued today. The Quality Score stands at 55/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of HK$3.03 per share, and 0 of the 13 models we run sit above the HK$31.46 price. Bear case: the Multiples group reads lowest at HK$2.07, and 13 of the 13 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Genscript Biotech Corp generated revenue of HK$960M at a net margin of −55.5%. Revenue grew 42.5% year over year. It earns a return on equity of −12.9%. Net debt stands at HK$116M. Fundamentals as of Aug 20, 2026
Our scenario range runs from HK$11.63 (bear case) to HK$19.42 (bull case); at HK$31.46, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at −59% fair-value upside, at −51%, 1548 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 13 models by family
Widest divergence: DCF Models (HK$3.03) versus Earnings-Based (HK$1.06). Highest evidence: FCF DCF (75).
Notify me when 1548 reaches fair value
Put 1548 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 73
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.
Full company description
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally. It operates through Life Science Services and Products; Biologics Development Services; and Industrial Synthetic Biology Products segments. The Life Science Services and Products segment provide research services and products which are used in fundamental to life-science research and application. The Biologics Development Services segment which helps biopharmaceutical and biotech companies accelerate the development of therapeutic antibodies, and gene/cell therapy products with an integrated platform. The Industrial Synthetic Biology Products segment develops and produces industrial enzymes through non-pathogenic microbial strains constructed using genetic engineering. It also offers SurePAGE, a precast gel series; CytoSinct, a Nanobeads product and services; and Benz-Neburase, a genetically engineered endonuclease. In addition, the company provides automated protein and antibody purification system; automated maxi-plasmid purification; automated mini-scale purification for plasmid, protein, and antibody; eBlot and eStain, a protein transfer and staining system; eZwest Lite, an automated western blotting device; CytoSinct, a cell isolation solution; pharmacokinetics and immunogenicity ELISA kits; COVID-19 detection cPass technology kits; and GenBox, a mini electrophoresis tank. It serves antibody drug discovery; gene therapy; vaccine; in vitro diagnostics; gene editing; plant biology; and synthetic biology solutions. The company was founded in 2002 and is headquartered in Wan Chai, Hong Kong.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Genscript Biotech Corp reported revenue of $960M in FY2025 versus $511M in FY2021, a compound +17.1%/yr. Reported net income was −$533M in FY2025.
1548 screens 103% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- GenScript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles
- Genscript Biotech Corp (GNNSF) (H1 2026) Earnings Call Highlights: Revenue Surges 27.3% to $404. ...
- GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation
- Genscript Biotech (SEHK:1548) Valuation Check After Recent Share Price Pullback
Peer Group
Biotechnology · 622 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| CSL Limited CSL | A$174.50 | A$141.68 | −19% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | −69% |
| BioNTech SE BNTX | $111.40 | $45.66 | −59% |
Compare Genscript Biotech Corp with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Genscript Biotech Corp (1548) overvalued or undervalued?
What is the fair value of 1548?
What is the quality score of 1548?
What is the revenue of Genscript Biotech Corp (1548)?
What is the net profit margin of 1548?
Watch Genscript Biotech Corp in the live analysis
One click puts Genscript Biotech Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.